Trade Rocket Pharmaceuticals Inc - RCKT CFD

Rocket Pharma Company profile

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include: Fanconi Anemia (FA), is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I (LAD-I), is a genetic disorder that causes the immune system to malfunction; Pyruvate Kinase Deficiency (PKD), is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia, and Infantile Malignant Osteopetrosis (IMO), is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rocket Pharmaceuticals Inc revenues was not reported. Net loss increased 21% to $169.1M. Higher net loss reflects research and development expense balanci increase of 15% to $113.5M (expense), General and administrative - Balancing increase of 47% to $24.5M (expense), Stock-based Compensation in SGA increase of 54% to $17.3M (expense).